Literature DB >> 24078631

An immunomodulating motif of the HIV-1 fusion protein is chirality-independent: implications for its mode of action.

Omri Faingold1, Avraham Ashkenazi, Nathali Kaushansky, Avraham Ben-Nun, Yechiel Shai.   

Abstract

An immunosuppressive motif was recently found within the HIV-1 gp41 fusion protein (termed immunosuppressive loop-associated determinant core motif (ISLAD CM)). Peptides containing the motif interact with the T-cell receptor (TCR) complex; however, the mechanism by which the motif exerts its immunosuppressive activity is yet to be determined. Recent studies showed that interactions between protein domains in the membrane milieu are not always sterically controlled. Therefore, we utilized the unique membrane leniency toward association between D- and L-stereoisomers to investigate the detailed mechanism by which ISLAD CM inhibits T-cell activation. We show that a D-enantiomer of ISLAD CM (termed ISLAD D-CM) inhibited the proliferation of murine myelin oligodendrocyte glycoprotein (MOG)-(35-55)-specific line T-cells to the same extent as the l-motif form. Moreover, the D- and L-forms preferentially bound spleen-derived T-cells over B-cells by 13-fold. Furthermore, both forms of ISLAD CM co-localized with the TCR on activated T-cells and interacted with the transmembrane domain of the TCR. FRET experiments revealed the importance of basic residues for the interaction between ISLAD CM forms and the TCR transmembrane domain. Ex vivo studies demonstrated that ISLAD D-CM administration inhibited the proliferation (72%) and proinflammatory cytokine secretion of pathogenic MOG(35-55)-specific T-cells. This study provides insights into the immunosuppressive mechanism of gp41 and demonstrates that chirality-independent interactions in the membrane can take place in diverse biological systems. Apart from HIV pathogenesis, the D-peptide reported herein may serve as a potential tool for treating T-cell-mediated pathologies.

Entities:  

Keywords:  Autoimmune Diseases; Immunosuppression; Membrane Fusion; Membrane Recognition; Protein-Protein Interactions; T-cell; Viral Fusion Protein

Mesh:

Substances:

Year:  2013        PMID: 24078631      PMCID: PMC3829137          DOI: 10.1074/jbc.M113.512038

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  57 in total

1.  Failure of HIV-exposed CD4+ T cells to activate dendritic cells is reversed by restoration of CD40/CD154 interactions.

Authors:  Rui Zhang; Jeffrey D Lifson; Claire Chougnet
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

2.  HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation.

Authors:  Francisco J Quintana; Doron Gerber; Sally C Kent; Irun R Cohen; Yechiel Shai
Journal:  J Clin Invest       Date:  2005-07-07       Impact factor: 14.808

3.  T-cell inactivation and immunosuppressive activity induced by HIV gp41 via novel interacting motif.

Authors:  Itai Bloch; Francisco J Quintana; Doron Gerber; Tomer Cohen; Irun R Cohen; Yechiel Shai
Journal:  FASEB J       Date:  2006-12-21       Impact factor: 5.191

4.  Peptides as transmembrane segments: decrypting the determinants for helix-helix interactions in membrane proteins.

Authors:  Arianna Rath; Rachel M Johnson; Charles M Deber
Journal:  Biopolymers       Date:  2007       Impact factor: 2.505

5.  D-enantiomer peptide of the TCRalpha transmembrane domain inhibits T-cell activation in vitro and in vivo.

Authors:  Doron Gerber; Francisco J Quintana; Itai Bloch; Irun R Cohen; Yechiel Shai
Journal:  FASEB J       Date:  2005-04-18       Impact factor: 5.191

6.  Vaccine-delivered HIV envelope inhibits CD4(+) T-cell activation, a mechanism for poor HIV vaccine responses.

Authors:  Kathy Fernando; Haitao Hu; Houping Ni; James A Hoxie; Drew Weissman
Journal:  Blood       Date:  2006-12-07       Impact factor: 22.113

7.  Role of the membrane-spanning domain of human immunodeficiency virus type 1 envelope glycoprotein in cell-cell fusion and virus infection.

Authors:  Liang Shang; Ling Yue; Eric Hunter
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

8.  A structurally altered D,L-amino acid TCRalpha transmembrane peptide interacts with the TCRalpha and inhibits T-cell activation in vitro and in an animal model.

Authors:  Francisco J Quintana; Doron Gerber; Itai Bloch; Irun R Cohen; Yechiel Shai
Journal:  Biochemistry       Date:  2007-02-09       Impact factor: 3.162

9.  Characterization of the interacting domain of the HIV-1 fusion peptide with the transmembrane domain of the T-cell receptor.

Authors:  Tomer Cohen; Meirav Pevsner-Fischer; Noam Cohen; Irun R Cohen; Yechiel Shai
Journal:  Biochemistry       Date:  2008-04-01       Impact factor: 3.162

10.  Pathogenic T cells in MOBP-induced murine EAE are predominantly focused to recognition of MOBP21F and MOBP27P epitopic residues.

Authors:  Nathali Kaushansky; Rina Zilkha-Falb; Reut Hemo; Hans Lassman; Miriam Eisenstein; Aldema Sas; Avraham Ben-Nun
Journal:  Eur J Immunol       Date:  2007-11       Impact factor: 5.532

View more
  2 in total

Review 1.  Peptides and peptidomimetics as immunomodulators.

Authors:  Ameya S Gokhale; Seetharama Satyanarayanajois
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

2.  The HTLV-1 gp21 fusion peptide inhibits antigen specific T-cell activation in-vitro and in mice.

Authors:  Etai Rotem; Omri Faingold; Meital Charni; Yoel A Klug; Daniel Harari; Liraz Shmuel-Galia; Alon Nudelman; Varda Rotter; Yechiel Shai
Journal:  PLoS Pathog       Date:  2018-05-04       Impact factor: 6.823

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.